In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co has announced the US launch of a mobile app designed to help and enhance communications between diabetes patients and educators. US-based Merck said the app known as map4health was ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Accra [Ghana]/ Mumbai (Maharashtra) [India], November 14: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks 'World Diabetes Day 2024' together with Africa's First Ladies, Ministries ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Adjusted for one-time items that included a 79-cent-a-share charge related to the business development deals, EPS came to $1.57, ahead of the FactSet consensus of $1.48. Sales rose 4% to $16.657 ...